Technology | May 28, 2013

FDA Clears Sensus Healthcare Radiotherapy System to Treat Keloids

The SRT-100 is an option to treat non-melanoma skin cancer and keloids.

May 28, 2013 — Sensus Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) to treat Keloids with the SRT-100. The SRT-100 is an alternative to surgery in treating non-melanoma skin cancer and now is approved to treat keloids caused by surgery or injury. Leading dermatologists and oncologists have found the SRT-100 superficial radiation therapy system to be a choice for their patients who are not good surgical candidates.  Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers and keloids in hospitals and private practice settings.

"Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100 percent. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences," said Mark S. Nestor, M.D., Ph.D., of the Center for Cosmetic Enhancement in Aventura, Fla.

"It is very fortunate that the FDA has approved the Sensus SRT-100, the first computerized, state-of-the-art, in-office SRT device for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in-office modality available to offer our keloid patients."

The SRT-100 has SharpBeam technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada and SFDA cleared and is manufactured in the United States.

For more information: www.sensushealthcare.com 

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init